Disarm Therapeutics to Begin Developing Therapy that Prevents Axonal Degeneration

22 September 2017

Source Multiple Sclerosis News Today:

Disarm Therapeutics has completed the first round of financing to develop a compound that prevents axonal degeneration in patients with multiple sclerosis (MS) and other neurodegenerative conditions.

The treatment approach is based on an earlier discovery at Washington University in St. Louis, showing that the enzyme SARM1 is a key driver of axon degeneration, a process that causes disability and progression in several diseases of the central, ocular, and peripheral nervous systems.

The discovery was published in the journal Neuron in March 2017. Researchers had earlier known that SARM1 was involved in the degeneration process, but thought that another, so-far unidentified enzyme was needed to perform key steps.  Read on. 

Blog categories: